Category: 357935-97-8

On January 18, 2018, Mellstedt, Haakan; Bystroem, Styrbjoern; Vaagberg, Jan; Olsson, Elisabeth published a patent.Related Products of 357935-97-8 The title of the patent was 2-Phenylimidazo[4,5-B]pyridin-7-amine derivatives used as inhibitors of mammalian tyrosine kinase ROR1 activity and their preparation. And the patent contained the following:

The invention provides compounds of formula I and II and their use as inhibitors of mammalian tyrosine kinase ROR1. Compounds of formula I and II, wherein R1 is C1-6 alkyl, C3-6 cycloalkyl-C1-6 alkyl, cyano-C1-6 alkyl, etc.; Ra is independently C1-6 alkyl; x is 0, 1, 2, 3 and 4; m is 1 and 2; R2 is Cl and Br; Rb is halo, C1-3 alkyl and C1-3 alkoxy; y is 0, 1, 2 and 3; W is QR4, O and N(R5)CO; Q is N and CH; R4 is C1-6 alkyl, cyano-C1-6 alkyl, C1-6 alkyl-SO2, etc.; Z is N and CH; R3 is independently C1-6 alkyl; p is 0, 1, 2 and 3; n is 0, 1 and 2; and pharmaceutically acceptable salt thereof, are claimed. Compound III was prepared by a multistep procedure (procedure given). Compounds were tested for mammalian tyrosine kinase ROR1 inhibitory activity (data given). The experimental process involved the reaction of 1-Ethylpiperidin-4-amine dihydrochloride(cas: 357935-97-8).Related Products of 357935-97-8

The Article related to imidazole pyridine derivative preparation ror1 inhibition, Heterocyclic Compounds (More Than One Hetero Atom): Imidazoles and other aspects.Related Products of 357935-97-8

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem

On September 2, 2021, Mellstedt, Haakan; Bystroem, Styrbjoern; Vaagberg, Jan; Olsson, Elisabeth published a patent.Quality Control of 1-Ethylpiperidin-4-amine dihydrochloride The title of the patent was 2-Phenylimidazo[4,5-B]pyridin-7-amine derivatives used as inhibitors of mammalian tyrosine kinase ROR1 activity and their preparation. And the patent contained the following:

The invention provides compounds of formula I and II and their use as inhibitors of mammalian tyrosine kinase ROR1. Compounds of formula I and II, wherein R1 is C1-6 alkyl, C3-6 cycloalkyl-C1-6 alkyl, cyano-C1-6 alkyl, etc.; Ra is independently C1-6 alkyl; x is 0, 1, 2, 3 and 4; m is 1 and 2; R2 is Cl and Br; Rb is halo, C1-3 alkyl and C1-3 alkoxy; y is 0, 1, 2 and 3; W is QR4, O and N(R5)CO; Q is N and CH; R4 is C1-6 alkyl, cyano-C1-6 alkyl, C1-6 alkyl-SO2, etc.; Z is N and CH; R3 is independently C1-6 alkyl; p is 0, 1, 2 and 3; n is 0, 1 and 2; and pharmaceutically acceptable salt thereof, are claimed. Compound III was prepared by a multistep procedure (procedure given). Compounds were tested for mammalian tyrosine kinase ROR1 inhibitory activity (data given). The experimental process involved the reaction of 1-Ethylpiperidin-4-amine dihydrochloride(cas: 357935-97-8).Quality Control of 1-Ethylpiperidin-4-amine dihydrochloride

The Article related to imidazole pyridine derivative preparation ror1 inhibition, Heterocyclic Compounds (More Than One Hetero Atom): Imidazoles and other aspects.Quality Control of 1-Ethylpiperidin-4-amine dihydrochloride

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem

On September 7, 2001, Adams, Jerry L.; Boehm, Jeffrey C.; Hall, Ralph F.; Taggart, John J. published a patent.Computed Properties of 357935-97-8 The title of the patent was Preparation of 1,5-disubstituted-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-ones for treatment of CSBP/p38 kinase mediated diseases. And the patent contained the following:

The title compounds (I) [wherein R1 = (un)substituted (hetero)aryl; R2 = H or (un)substituted (cyclo)alkyl(alkyl), (hetero)aryl(alkyl), or heterocyclyl(alkyl); R3 = (un)substituted (cyclo)alkyl(alkyl), (hetero)aryl(alkyl), or heterocyclyl(alkyl); Y = a bond, CRb, CO, NRd, O, or SOm; Rb = H, alkyl, NRc, OH, SH, alkoxy, or SOm-alkyl; Rc and Rd = independently H or alkyl; X = R2, OR2, SOmR2, or (un)substituted (CH2)nNH2; m = 0-2; n = 0-10; or pharmaceutically acceptable salts thereof] were prepared as CSBP/p38 kinase inhibitors. For example, 4,6-dichloro-2-methylsulfanylpyrimidine-5-carbonitrile was condensed with aniline, followed by arylation with PhB(OH)2, reduction of the nitrile using LAH in Et2O, and cyclocondensation of the diamine with COCl2 in toluene and pyridine, to give II. Representative compounds I inhibited CSBP/p38 kinase with IC50 values of < 100 μM. Applications of I to a wide variety of arthritic, inflammatory, proliferative, and viral conditions are specifically claimed. The experimental process involved the reaction of 1-Ethylpiperidin-4-amine dihydrochloride(cas: 357935-97-8).Computed Properties of 357935-97-8

The Article related to pyrimidopyrimidinone preparation csbp p38 kinase inhibitor, antiarthritic antiinflammatory immunosuppressant antiviral antitumor pyrimidopyrimidinone preparation, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Computed Properties of 357935-97-8

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem

On April 22, 2021, Boyle, Robert George; Walker, David Winter; Major, Meriel Ruth published a patent.Computed Properties of 357935-97-8 The title of the patent was Preparation of pyrrolo[2,3-d]pyrimidine derivatives and their use in the treatment of cancer. And the patent contained the following:

The title compounds I [A = CH or N; R1 = C(OH)(Alk1)(Alk2), N:S(O)(Alk3)(Alk4), or Q; Alk1, Alk2 = same or different C1-3 saturated hydrocarbyl; or Alk1 and Alk2 together with the carbon atom to which they are attached form a C3-4 cycloalkyl ring; Alk3, Alk4 = same or different C1-3 hydrocarbyl; or Alk3 and Alk4 together with the sulfur atom to which they are attached form a 4-6 membered thiacycloalkyl ring; p = 1,2; q = 1,2, provided that the sum of p + q is either 2 or 3; R8 = H, F or Me; R2 = H, halo, C1-3 alkyl C1-3 alkoxy, or C1-3 fluoroalkyl; R3 = H, F, or Me; R4 = H, F, Me, or cyano; R5 = L-Cyc1; L = (CH2)m-B-(CH2)n; m, n = independently 0 or 1; B = absent or C(O)N(Rc), N(Rc)C(O), N(Rc), O, N(Rc)CH2C(O), S, S(O), or S(O)2; Rc = H or C1-4 hydrocarbyl; Cyc1 = each (un)substituted C3-6 cycloalkyl, 4- to 7-membered monocyclic or heterocyclic group containing 1 or 2 heteroatoms selected from N and O, 7- to 11-membered bicyclic heterocyclic group containing 1 or 2 heteroatoms selected from N and O, or phenyl; R6 = H, halo, C1-4 alkyl, C1-4 alkoxy, or C1-4 fluoroalkyl; R7 = C1-4 hydrocarbyl, halo, hydroxy, oxo, C(O)Ra, C(O)ORa, C(O)N(Ra)(Rb), N(Rb)C(O)Ra, N(Rb)C(O)N(Ra)(Rb), or C2-5alkane-diyl, wherein the C2-5alkane-diyl group together with an atom or atoms of Cyc1 to which it is attached forms a cyclic group; Ra, Rb = independently H or C1-3 hydrocarbyl] are prepared The compounds I also including or salts or tautomers thereof are inhibitors of Wee1 kinase and/or PLK1 kinase and are envisaged to be useful in the treatment of cancers. Thus, 2-chloro-5-fluoro-7H-pyrrolo[2,3-d]pyrimidine was coupled with 2-(6-bromo-2-pyridyl)propanol in the presence of CuI, trans-N,N’-dimethylcyclohexane, and K3PO4 in 1,4-dioxane at 100° for 12 h under nitrogen to give 98% 2-[6-(2-chloro-5-fluoropyrrolo[2,3-d]pyrimidin-7-yl)-2-pyridyl]propan-2-ol which was coupled with tert-Bu 4-(4-aminophenyl)piperazine-1-carboxylate in the presence of Li-HMDS in THF at 0° for 30 min and at 100° for 2 h to give 40% tert-Bu 4-[4-[[5-fluoro-7-[6-(1-hydroxy-1-methylethyl)-2-pyridyl]pyrrolo[2,3-d]pyrimidin-2-yl]amino]phenyl]piperazine-1-carboxylate (II; R = Boc). II (R = Boc) was treated with 4 N HCl/1,4-dioxane at room temperature for 2 h to give 70% 2-[6-[5-fluoro-2-[4-(piperazin-1-yl)anilino]pyrrolo[2,3-d]pyrimidin-7-yl]-2-pyridyl]propan-2-ol dihydrochloride II·2HCl (R = H). II·2HCl (R = H) and 2-[6-[2-[3-chloro-4-(piperazin-1-yl)anilino]-5-fluoropyrrolo[2,3-d]pyrimidin-7-yl]-2-pyridyl]propan-2-ol dihydrochloride (III) showed IC50 of 0.010μM, resp., against human Weel kinase. The experimental process involved the reaction of 1-Ethylpiperidin-4-amine dihydrochloride(cas: 357935-97-8).Computed Properties of 357935-97-8

The Article related to pyrrolopyrimidine preparation treatment cancer, wee1 kinase plk1 kinase inhibitor pyrrolopyrimidine preparation, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Computed Properties of 357935-97-8

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem

On October 29, 2020, Scully, Stephen S.; Laplaca, Derek; Pelly, Rachel; Parmar, Rubina Giare; Maetani, Micah published a patent.Application of 357935-97-8 The title of the patent was Preparation of ionizable amine lipids and lipid nanoparticles. And the patent contained the following:

Ionizable amine lipids of formula I [X1 = O, (substituted) NH, bond; X2 = alkylene; X3 = CO, bond; R1 = H, Me; R2, R3 = alkyl; R2X2N = heterocyclyl; R2R3N = heterocyclyl; Y1 = alkylene; Y2 = CH2CH=CH, CO-OCH2CH=CH, CO-O; n = 0-3; R4 = alkyl; Z1 = alkylene, bond; Z2 = CO-O, absent; R5, R6 = alkyl, alkoxy; W = methylene, bond; R7 = H, Me] are prepared which are useful for the delivery of biol. active agents, for example delivering biol. active agents to cells to prepare engineered cells. The ionizable amine lipids disclosed herein are useful as ionizable lipids in the formulation of lipid nanoparticle-based compositions Thus, II was prepared, and had editing efficiency of 23.74% at 0.1 mg/kg, 58.48% at 0.3 mg/kg and 73.6% at 1 mg/kg in mice liver. The experimental process involved the reaction of 1-Ethylpiperidin-4-amine dihydrochloride(cas: 357935-97-8).Application of 357935-97-8

The Article related to lipid nanoparticle ionizable amine lipid preparation, Biomolecules and Their Synthetic Analogs: Prostaglandins and Other Arachidonic Acid Cascade Substances, Thromboxanes, Fatty Acids and other aspects.Application of 357935-97-8

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem